Research programme: anticancer antibodies - Cancer Research UK/MedImmune

Drug Profile

Research programme: anticancer antibodies - Cancer Research UK/MedImmune

Alternative Names: 264RAD; Cancer therapeutics - Cancer Research UK/MedImmune

Latest Information Update: 09 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cancer Research UK; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Pancreatic cancer

Most Recent Events

  • 01 Jul 2016 Early research in Pancreatic cancer in United Kingdom (Parenteral)
  • 25 Sep 2014 Cancer Research UK and MedImmune collaborate to establish CRUK-MEDI Alliance Laboratory
  • 25 Sep 2014 Early research in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top